Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 15/20 | 0.49 |
| ▸ | PLK3 | Q9H4B4 | 12/20 | 0.49 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3253745 | 0.94 | PLK1 (0.51) | PLK1PLK3IKBKECDK2 | |
| SCHEMBL13440023 | 0.94 | PLK1 (0.51) | PLK1PLK3IKBKECDK2 | |
| SCHEMBL3615079 | 0.90 | PLK1 (0.52) | PLK1PLK3IKBKECDK2 | |
| SCHEMBL3610941 | 0.88 | PLK1 (0.53) | PLK1PLK3IKBKECDK2 | |
| SCHEMBL3614266 | 0.87 | PLK1 (0.63) | PLK1PLK3IKBKECDK2 | |
| SCHEMBL3603182 | 0.85 | PLK1 (0.48) | PLK1PLK3IKBKECDK2 | |
| SCHEMBL3606147 | 0.84 | PLK1 (0.61) | PLK1PLK3IKBKECDK2 | |
| SCHEMBL13440042 | 0.84 | PLK1 (0.52) | PLK1PLK3IKBKECDK2 | |
| SCHEMBL3259164 | 0.84 | PLK1 (0.52) | PLK1PLK3IKBKECDK2 | |
| SCHEMBL3615343 | 0.83 | PLK1 (0.69) | PLK1PLK3IKBKE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1601656-A4 | TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-06-11 | — | — | EP | claimed |
| US-7138412-B2 | Tetrahydroquinoline derivatives useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-21 | — | — | US | claimed |
| EP-1601656-A1 | TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-12-07 | — | — | EP | claimed |
| US-20040235847-A1 | Tetrahydroquinoline derivatives useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-25 | — | — | US | claimed |
| WO-2004080971-A1 | TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-09-23 | — | — | WO | claimed |
| US-7709646-B2 | Tetrahydroquinoline derivatives useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-05-04 | — | — | US | disclosed |
| US-20100075960-A1 | BENZIMIDAZOLE THIOPHENE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2010-03-25 | — | — | US | disclosed |
| EP-1601656-A4 | TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-06-11 | — | — | EP | disclosed |
| US-7138412-B2 | Tetrahydroquinoline derivatives useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-21 | — | — | US | disclosed |
| US-20060223854-A1 | Tetrahydroquinoline derivatives useful as serine protease inhibitors | QUAN MIMI L | 2006-10-05 | — | — | US | disclosed |
| EP-1601656-A1 | TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-12-07 | — | — | EP | disclosed |
| US-20040235847-A1 | Tetrahydroquinoline derivatives useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-25 | — | — | US | disclosed |
| WO-2004080971-A1 | TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235847-A1 | Tetrahydroquinoline derivatives useful as serine protease inhibitors | TFPI, F2, TFPI2 | PLK1 974/4885PLK3 1192/4885IKBKE 192/4885 |
| US-20060223854-A1 | Tetrahydroquinoline derivatives useful as serine protease inhibitors | F12, F2, TFPI | PLK1 945/4885PLK3 831/4885IKBKE 356/4885 |
| US-20100075960-A1 | BENZIMIDAZOLE THIOPHENE COMPOUNDS | ABCB1, CYP3A5, CYP3A4 | PLK1 450/4885PLK3 1025/4885IKBKE 1461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.